Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good Morning JamesF1
This may be true, maybe not.
Prasco does not have its own amphetamine quota.
Elite's generic Adderall seems fairly well-liked online.
We agree on this, imanjen13.
DSherman thanks for re-reading my month-old post.
A whole lot of indemnification going on...
Dilution and indemnification, funny how often those two run in the same circles. Everyone recognizes the Mikah entanglements will present a major obstacle to Elite's acquisition. Here you see the company trying to protect the officers from what they know is coming. Instead of fairly and transparently dealing with this issue now while stock price is 15 cents, they will kick the can down the road farther and farther as the barrier to acquisition gets larger and larger. Why? Because Hakim has everything to gain, and shareholders have everything to lose.
Maybe you should consider a hobby.
It has nothing to do with a typo.
Unnecessary.
This one takes the cake.
We are so lucky to have you.
I apologize.
Good morning JamesF1,
Thanks for your opinion Kayak.
Good morning meschcan,
Paragraph IV Certifications
https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/patent-certifications-and-suitability-petitions#List
If you go this page, then click on the link for New Paragraph IV Certifications as of November 27, 2023. Scroll down to page 62. The relevant listing is Oxycontin (NDA 022272). It shows 1 ANDA submitted for every strength, except 2 ANDA's for the 20mg size. It says "as of November 27, 2023," but I have no idea if our certification is included in these numbers. There are two especially interesting parts: the middle column "180 DAY STATUS" and the far right column "EXPIRATION DATE OF LAST QUALIFYING PATENT." For Oxycontin (NDA 022272), it lists 180 day status as "extinguished" and the expiration of last qualifying patent as 4/19/2025.
These types of decisions are complicated and murky, and I really don't know what any of this means. My best guess is that the FDA has decided nobody will get 180 day exclusivity, and at least for these two ANDA applicants, the FDA has decided on 4/19/25 as an important day. It seems to me that everyone in line on that day could get a green light at the same time. I don't know if a patent expiration on 4/19/25 would have any effect on the automatic 30 month stay triggered by Purdue's Paragraph IV response.
.
They really DO exist...
I found the foreign shorties everybody keeps talking about. Not sure how significantly this affects our Israeli partner.
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4652027